Delivery Order SPE2DB24D2003-SPE2DB25FXLN4
- Not listed
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of...
- The Defense Logistics Agency awarded a $2,558.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injectors. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.99 billion ceiling value through December 2026. The delivery order is non-set-aside and was competitively awarded. Performance will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,375.49. The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. Performance will be executed from the company's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order represents a...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,293.84 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same municipality....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xyosted 50 mg/0.5 ml auto-injector units, valued at $1,780.19. This firm fixed-price delivery order, with an ultimate completion date of August 1, 2025, represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX, valued at $999,999,999.00 through December 2026). The order will be fulfilled from the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,188.98 on July 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 23, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLN4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector medication valued at $1,127.92. This is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger prime indefinite delivery contract (IDC SPE2DX) with DLA Troop Support Medical, which carries a ceiling value of $999,999,999 through December 2026. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor and critical federal medical procurement vendor, primarily supporting Defense Health Agency and military healthcare systems. The company's DLA prime contract vehicle enables the supply of a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs globally. This particular delivery order for the testosterone replacement therapy medication Xyosted reflects the company's continued role in fulfilling specialized pharmaceutical requirements for federal medical supply chains through competitively awarded, firm fixed price transactions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/11/25 |